Skip to main content

Verrica Pharmaceuticals Inc. (VRCA)

NASDAQ: VRCA · Delayed Price · USD
11.25
-0.58 (-4.90%)
After-hours:Sep 23, 2021 7:35 PM EDT
11.83
0.57 (5.06%)
At close: Sep 23, 4:00 PM
Market Cap325.50M
Revenue (ttm)12.00M
Net Income (ttm)-36.17M
Shares Out27.51M
EPS (ttm)-1.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume256,571
Open11.34
Previous Close11.26
Day's Range10.86 - 12.14
52-Week Range7.05 - 18.42
Beta2.27
AnalystsStrong Buy
Price Target19.83 (+67.6%)
Est. Earnings DateNov 9, 2021

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agr...

IndustryPharmaceuticals
IPO DateJun 15, 2018
CEOTed White
Employees29
Stock ExchangeNASDAQ
Ticker SymbolVRCA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for VRCA stock is "Strong Buy." The 12-month stock price forecast is 19.83, which is an increase of 67.62% from the latest price.

Price Target
$19.83
(67.62% upside)
Analyst Consensus: Strong Buy

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Verrica Pharmaceuticals Inc. -VRCA

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA).

1 day ago - PRNewsWire

Why Verrica Pharmaceuticals Stock Is Getting Pummeled Today

The Food and Drug Administration delivered some bad news regarding the company's dermatology candidate.

2 days ago - The Motley Fool

Why Verrica Pharmaceuticals Shares Are Trading Lower Today

Verrica Pharmaceuticals (NASDAQ:VRCA) shares are trading lower after the company announced the FDA issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of mo...

2 days ago - Benzinga

Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug

Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.

2 days ago - Zacks Investment Research

Verrica Pharma Shares Slide After Response Letter From FDA

The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application seeking approval for VP-102 for molluscum contagiosum, a highly contagiou...

3 days ago - Benzinga

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Co...

No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer

3 days ago - GlobeNewsWire

Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

1 month ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

Company strengthens management team in anticipation of  the potential commercial launch of VP-102, if approved

2 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such inves...

3 months ago - Newsfile Corp

Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed

Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three mo...

3 months ago - Zacks Investment Research

Verrica's VP-102 Application Review for Molluscum Contagiosum Delayed till September

The FDA has extended the review period for the marketing application for Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) VP-102 to treat molluscum contagiosum (molluscum). Now the Prescription Drug User Fe...

3 months ago - Benzinga

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum...

– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 –

3 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference

WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

3 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

4 months ago - GlobeNewsWire

Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results

– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 –

4 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic...

5 months ago - GlobeNewsWire

Verrica Announces Election of Gary Goldenberg, MD, Verrica's Chief Medical Officer, to Membership in the American Der...

WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

5 months ago - GlobeNewsWire

Verrica Announces Pricing of Public Offering of Common Stock

WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

6 months ago - GlobeNewsWire

Verrica Announces Proposed Public Offering of Common Stock

WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical intervent...

6 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Co...

Torii to make upfront payment of $11.5 million to Verrica in addition to other potential milestone payments of up to $58 million and, if marketed in Japan, tiered transfer price payments as a percentage...

6 months ago - GlobeNewsWire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results

– FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 –

6 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference

WEST CHESTER, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic...

6 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference

WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

7 months ago - GlobeNewsWire

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in ...

- In new post hoc analyses of the Phase 3 molluscum trials segmenting molluscum lesions by body region and study visit, the percentage of participants with complete clearance of all baseline and new mol...

8 months ago - GlobeNewsWire